(Reuters) - Ariad Pharmaceuticals Inc said its experimental lung cancer drug was granted "breakthrough therapy" status by the U.S. Food and Drug Administration, sending the company's shares up as much as 13 percent. The designation hastens the development and review periods of a drug that shows evidence of providing improvement over existing treatment for patients with serious diseases. The drug, AP26113, is designed to treat non-small cell lung cancer (NSCLC) with a specific gene mutation. About 1. ...
via Health News Headlines - Yahoo News http://ift.tt/1vcAkha
via Health News Headlines - Yahoo News http://ift.tt/1vcAkha
No comments:
Post a Comment